Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response

References

• Fries JF. Aging, natural death, and the compression of morbidity. N. Engl. J. Med.303(3), 130–135 (1980).
   PubMed Web of Science ®Google Scholar
• Fries JF. Compression of morbidity in the elderly. Vaccine18(16), 1584–1589 (2000).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. Am. J. Epidemiol.160(5), 492–502 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA277(9), 728–734 (1997).
   PubMed Web of Science ®Google Scholar
• Falsey AR. Respiratory syncytial virus infection in adults. Semin. Respir. Crit. Care Med.28(2), 171–181 (2007).
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine25(5), 846–855 (2007).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc.40(2), 115–119 (1992).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging22(7), 577–587 (2005).
   PubMed Web of Science ®Google Scholar
• Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect. Dis.4(2), 112–124 (2004).
   PubMed Web of Science ®Google Scholar
• Mufson MA. Pneumococcal infections. JAMA246(17), 1942–1948 (1981).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med.348(18), 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Fedullo AJ, Swinburne AJ. Relationship of patient age to clinical features and outcome for in-hospital treatment of pneumonia. J. Gerontol.40(1), 29–33 (1985).
   PubMedGoogle Scholar
• O’Keeffe S, Lavan J. The prognostic significance of delirium in older hospital patients. J. Am. Geriatr. Soc.45(2), 174–178 (1997).
   PubMed Web of Science ®Google Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch. Intern. Med.155(15), 1605–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med.58, 9–20 (1965).
   PubMedGoogle Scholar
• Schmader K. Herpes zoster in older adults. Clin. Infect. Dis.32(10), 1481–1486 (2001).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol. Infect.127(2), 305–314 (2001).
   PubMed Web of Science ®Google Scholar
• Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep.55(RR-17), 1–37 (2006).
   PubMedGoogle Scholar
• Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol.8(4), 369–377 (2007).
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol.8(6), 639–646 (2007).
   PubMed Web of Science ®Google Scholar
• Laurence A, O’Shea JJ. TH-17 differentiation: of mice and men. Nat. Immunol.8(9), 903–905 (2007).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol.176(10), 6333–6339 (2006).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet2(8252), 887–891 (1981).
   PubMed Web of Science ®Google Scholar
• Musher DM, Phan HM, Watson DA, Baughn RE. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. J. Infect. Dis.182(1), 158–167 (2000).
   PubMed Web of Science ®Google Scholar
• Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J. Infect. Dis.183(5), 827–830 (2001).
   PubMed Web of Science ®Google Scholar
• Briles DE. Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine? Mech. Ageing Dev.125(2), 129–131 (2004).
   PubMed Web of Science ®Google Scholar
• Baril L, Dietemann J, Essevaz-Roulet M et al. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin. Exp. Immunol.145(2), 277–286 (2006).
   PubMed Web of Science ®Google Scholar
• Perry FE, Catterall JR. The pneumococcus: host–organism interactions and their implications for immunotherapy and immunoprophylaxis. Thorax49(10), 946–950 (1994).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway C Jr. The Toll receptor family and microbial recognition. Trends Microbiol.8(10), 452–456 (2000).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate Toll-like receptor gene expression in viral infections. Genes Immun.2(6), 349–355 (2001).
   PubMed Web of Science ®Google Scholar
• Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA101(15), 5598–5603 (2004).
   PubMed Web of Science ®Google Scholar
• Qureshi ST, Medzhitov R. Toll-like receptors and their role in experimental models of microbial infection. Genes Immun.4(2), 87–94 (2003).
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol.21, 335–376 (2003).
   PubMed Web of Science ®Google Scholar
• Underhill DM. Toll-like receptors: networking for success. Eur. J. Immunol.33(7), 1767–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science298(5595), 1025–1029 (2002).
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of Hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med.195(1), 99–111 (2002).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr. Top. Microbiol. Immunol.270, 169–184 (2002).
   PubMed Web of Science ®Google Scholar
• Heil F, Ahmad-Nejad P, Hemmi H et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol.33(11), 2987–2997 (2003).
   PubMed Web of Science ®Google Scholar
• West MA, Wallin RP, Matthews SP et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science305(5687), 1153–1157 (2004).
   PubMed Web of Science ®Google Scholar
• Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol.169(9), 4697–4701 (2002).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O’Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine21(17–18), 2133–2144 (2003).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351(22), 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis.198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med.331(12), 778–784 (1994).
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine20(13–14), 1831–1836 (2002).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med.348(14), 1322–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine21(16), 1769–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med.357(14), 1373–1381 (2007).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA283(4), 499–505 (2000).
   PubMed Web of Science ®Google Scholar
• Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch. Intern. Med.158(6), 645–650 (1998).
   PubMedGoogle Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352(17), 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272(21), 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis.7(10), 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet372(9636), 398–405 (2008).
   PubMed Web of Science ®Google Scholar
• Jansen AG, Sanders EA, Nichol KL, van Loon AM, Hoes AW, Hak E. Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. Vaccine26(44), 5567–5574 (2008).
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The decline in vaccine efficacy with aging is well recognized and there is no doubt that recent advances in vaccine technology offer an unprecedented opportunity to improve influenza vaccines for older adults. Aging Health4(1), 33–35 (2008).
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18–64 years with diabetes or asthma – United States, 2003. MMWR53(43), 1007–1012 (2004).
   PubMedGoogle Scholar
• Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled [see comments]. JAMA277(9), 728–734 (1997).
   PubMed Web of Science ®Google Scholar
• Virelizier JL, Postlethwaite R, Schild GC, Allison AC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory. J. Exp. Med.140(6), 1559–1570 (1974).
   PubMed Web of Science ®Google Scholar
• de Bruijn IA, Remarque EJ, Beyer WE, le Cessie S, Masurel N, Ligthart GJ. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. Vaccine15(12–13), 1323–1329 (1997).
   PubMed Web of Science ®Google Scholar
• de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis.179(1), 31–36 (1999).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am. J. Epidemiol.127(2), 353–364 (1988).
   PubMed Web of Science ®Google Scholar
• Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet346(8975), 591–595 (1995).
   PubMed Web of Science ®Google Scholar
• Voordouw AC, Sturkenboom MC, Dieleman JP et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA292(17), 2089–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J. Infect. Dis.197(4), 490–502 (2008).
   PubMed Web of Science ®Google Scholar
• Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science249(4972), 1028–1030 (1990).
   PubMed Web of Science ®Google Scholar
• Hackett CJ, Yewdell JW, Bennink JR, Wysocka M. Class II MHC-restricted T cell determinants processed from either endosomes or the cytosol show similar requirements for host protein transport but different kinetics of presentation. J. Immunol.146(9), 2944–2951 (1991).
   PubMed Web of Science ®Google Scholar
• Lamb CA, Yewdell JW, Bennink JR, Cresswell P. Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus. Proc. Natl Acad. Sci. USA88(14), 5998–6002 (1991).
   PubMed Web of Science ®Google Scholar
• Askonas BA, Mullbacher A, Ashman RB. Cytotoxic T-memory cells in virus infection and the specificity of helper T cells. Immunology45(1), 79–84 (1982).
   PubMed Web of Science ®Google Scholar
• Hosaka Y, Sasao F, Yamanaka K, Bennink JR, Yewdell JW. Recognition of noninfectious influenza virus by class I-restricted murine cytotoxic T lymphocytes. J. Immunol.140(2), 606–610 (1988).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med.309(1), 13–17 (1983).
   PubMed Web of Science ®Google Scholar
• Pasternack MS, Eisen HN. A novel serine esterase expressed by cytotoxic T lymphocytes. Nature314(6013), 743–745 (1985).
   PubMed Web of Science ®Google Scholar
• Bleackley RC, Lobe CG, Duggan B et al. The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes. Immunol. Rev.103, 5–19 (1988).
   PubMed Web of Science ®Google Scholar
• Jenne DE, Tschopp J. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation. Immunol. Rev.103, 53–71 (1988).
   PubMed Web of Science ®Google Scholar
• Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature377(6548), 446–448 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson BJ, Costelloe EO, Fitzpatrick DR et al. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc. Natl Acad. Sci. USA100(5), 2657–2662 (2003).
   PubMed Web of Science ®Google Scholar
• Lawrence CW, Ream RM, Braciale TJ. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol.174(9), 5332–5340 (2005).
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Kedzierska K, Doherty PC, Turner SJ. Heterogeneity of effector phenotype for acute phase and memory influenza A virus-specific CTL. J. Immunol.179(1), 64–70 (2007).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977–82. Lancet2(8353), 762–764 (1983).
   PubMed Web of Science ®Google Scholar
• Nguyen HH, Moldoveanu Z, Novak MJ et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8+ cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology254(1), 50–60 (1999).
   PubMed Web of Science ®Google Scholar
• Ray SJ, Franki SN, Pierce RH et al. The collagen binding α1β1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity20(2), 167–179 (2004).
   PubMed Web of Science ®Google Scholar
• Powers DC. Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age [see comments]. J. Am. Geriatr. Soc.41(1), 1–5 (1993).
   PubMed Web of Science ®Google Scholar
• Mbawuike IN, Lange AR, Couch RB. Diminished influenza A virus-specific MHC class I-restricted cytotoxic T lymphocyte activity among elderly persons. Viral Immunol.6(1), 55–64 (1993).
   PubMedGoogle Scholar
• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine23(Suppl. 1), S10–S25 (2005).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J. Clin. Microbiol.28(11), 2539–2550 (1990).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O’Connor TZ, Newman FK et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J. Infect. Dis.190(1), 11–19 (2004).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine27, 2418–2425 (2009).
   PubMed Web of Science ®Google Scholar
• Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell3(4), 161–167 (2004).
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine23(Suppl. 1), S26–S38 (2005).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine23(3), 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol.152(4), 1653–1661 (1994).
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Stott EJ, Taylor G, Askonas BA. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology62(1), 133–138 (1987).
   PubMed Web of Science ®Google Scholar
• Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med.315(2), 77–81 (1986).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol.89, 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis.195(8), 1126–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Heidema J, Lukens MV, van Maren WW et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J. Immunol.179(12), 8410–8417 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis.190(2), 373–378 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol.73(2), 295–299 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Gilmore X, Xu K, Wyde PR, Mbawuike IN. An aged mouse model for RSV infection and diminished CD8+ CTL responses. Exp. Biol. Med. (Maywood)227(2), 133–140 (2002).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis.185(5), 682–685 (2002).
   PubMed Web of Science ®Google Scholar
• Wald TG, Miller BA, Shult P, Drinka P, Langer L, Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J. Am. Geriatr. Soc.43(2), 170–174 (1995).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines – nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis.198(9), 1317–1326 (2008).
   PubMed Web of Science ®Google Scholar
• Huang YP, Gauthey L, Michel M et al. The relationship between influenza vaccine-induced specific antibody responses and vaccine-induced nonspecific autoantibody responses in healthy older women. J. Gerontol.47(2), M50–55 (1992).
   Google Scholar
• Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J. Immunol.172(9), 5194–5199 (2004).
   PubMed Web of Science ®Google Scholar
• Khan AQ, Lees A, Snapper CM. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J. Immunol.172(1), 532–539 (2004).
   PubMed Web of Science ®Google Scholar
• Kemp K, Bruunsgaard H, Skinhoj P, Klarlund Pedersen B. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect. Immun.70(9), 5019–5025 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA285(13), 1729–1735 (2001).
   PubMed Web of Science ®Google Scholar
• Arva E, Andersson B. Induction of phagocyte-stimulating and Th1-promoting cytokines by in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand. J. Immunol.49(4), 417–423 (1999).
   PubMed Web of Science ®Google Scholar
• Khan AQ, Shen Y, Wu ZQ, Wynn TA, Snapper CM. Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae. Infect. Immun.70(2), 749–761 (2002).
   PubMed Web of Science ®Google Scholar
• Modlin RL, Nutman TB. Type 2 cytokines and negative immune regulation in human infections. Curr. Opin. Immunol.5(4), 511–517 (1993).
   PubMed Web of Science ®Google Scholar
• van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis.174(5), 994–1000 (1996).
   PubMed Web of Science ®Google Scholar
• Sun K, Salmon SL, Lotz SA, Metzger DW. Interleukin-12 promotes γ interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun.75(3), 1196–1202 (2007).
   PubMed Web of Science ®Google Scholar
• Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection. Nat. Med.14(5), 558–564 (2008).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clin. Geriatr. Med.8(1), 183–199 (1992).
   PubMedGoogle Scholar
• Sisk JE, Moskowitz AJ, Whang W et al. Cost–effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA278(16), 1333–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis.47(10), 1328–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine27(10), 1504–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun.67(11), 5979–5984 (1999).
   PubMed Web of Science ®Google Scholar
• Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis.173(2), 387–393 (1996).
   PubMed Web of Science ®Google Scholar
• Kolibab K, Smithson SL, Rabquer B, Khuder S, Westerink MA. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect. Immun.73(11), 7465–7476 (2005).
   PubMed Web of Science ®Google Scholar
• Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis.17(1), 66–73 (1993).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis.7(9), 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine25(20), 4029–4037 (2007).
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmole-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis.46(7), 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J. Infect. Dis.198(7), 1019–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J. Infect. Dis.190(1), 72–82 (2004).
   PubMed Web of Science ®Google Scholar
• Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine20(19–20), 2500–2507 (2002).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect.125(3), 651–669 (2000).
   PubMed Web of Science ®Google Scholar
• Patel MS, Gebremariam A, Davis MM. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect. Control Hosp. Epidemiol.29(12), 1157–1163 (2008).
   PubMed Web of Science ®Google Scholar
• Cohrs RJ, Gilden DH, Mahalingam R. Varicella zoster virus latency, neurological disease and experimental models: an update. Front. Biosci.9, 751–762 (2004).
   PubMed Web of Science ®Google Scholar
• Baiker A, Fabel K, Cozzio A et al. Varicella-zoster virus infection of human neural cells in vivo. Proc. Natl Acad. Sci. USA101(29), 10792–10797 (2004).
   PubMed Web of Science ®Google Scholar
• Arvin AM, Moffat JF, Redman R. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv. Virus Res.46, 263–309 (1996).
   PubMed Web of Science ®Google Scholar
• Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-α. J. Exp. Med.200(7), 917–925 (2004).
   PubMed Web of Science ®Google Scholar
• Hill JA, Benoist C, Mathis D. Treg cells: guardians for life. Nat. Immunol.8(2), 124–125 (2007).
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med.352(22), 2271–2284 (2005).
   PubMed Web of Science ®Google Scholar
• Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis.197(Suppl. 2), S207–S215 (2008).
   PubMed Web of Science ®Google Scholar
• Levin MJ, Smith JG, Kaufhold RM et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J. Infect. Dis.188(9), 1336–1344 (2003).
   PubMed Web of Science ®Google Scholar
• Smith JG, Levin M, Vessey R et al. Measurement of cell-mediated immunity with a Varicella–zoster virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J. Med. Virol.70(Suppl. 1), S38–S41 (2003).
   Google Scholar
• Levin MJ, Oxman MN, Zhang JH et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis.197(6), 825–835 (2008).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended adult immunization schedule – United States, 2009. MMWR57(53) 1–4 (2008).
   PubMedGoogle Scholar